Descriptive study of the effects of treprostinil and/or epoprostenol in newborn infants with inhaled NO refractory persistent pulmonary hypertension of the newborn (PPHN) - 29/10/26
, Sébastien Mur b, c, Géraldine Gascoin d, e, Laurent Storme b, c, Nicolas Joram f, Caroline Viard g, Yves Dulac h, Marine Butin i, j, Sophie Breinig a, eAbstract |
Background |
Epoprostenol and treprostinil, prostacyclin analogues, are used in some neonatal intensive care units (NICU) in the treatment of persistent pulmonary hypertension of the newborn (PPHN) refractory to inhaled nitric oxide (iNO). The aim of this retrospective multicentric descriptive study was to assess the profile and evolution of these newborns.
Methods |
Inclusion of neonates born ≥ 34 weeks of gestational age (WGA) and aged ≤ 28 days of life, presenting clinical signs of PPHN (respiratory and/or hemodynamic lability), and at least one echocardiographic sign of pulmonary hypertension. We collected data on the use of prostacyclin analogues, their tolerance, and their efficacy, by collecting clinical, biological, and echocardiographic data of these newborns.
Results |
Seventy patients were included from 4 French NICU. It appears that there may be an improvement in pulmonary hypertension (PH) at the initiation of prostacyclin analogues, showing by an increase in post-ductal SpO 2 , a decrease in FiO 2 and an improvement in PH’level on echocardiography. Only four patients needed a treatment discontinuation due to poor hemodynamic tolerance.
Conclusion |
Our study highlighted the safety of the use of epoprostenol and treprostinil in neonates suffering from iNO refractory PPHN, without significant adverse effect. It appears to be necessary to carry out further study to establish recommendations for the management of PPHN, and also to define more precisely the place of treprostinil and epoprostenol in this pathology.
Le texte complet de cet article est disponible en PDF.Keywords : Newborn, Infant, Persistent pulmonary hypertension of the newborn, Pulmonary hypertension, Treprostinil, Epoprostenol, Prostacyclin analogues, Congenital diaphragmatic hernia
Plan
Vol 81 - N° 5
P. 408-415 - septembre 2026 Retour au numéro
Article précédent
- #Clozapine through the lens of Instagram
- Jérémy Couturas, Marie-Lyne Pradal, Adrien Maurel, Mirvat Hamdan-Dumont, Laurence Schadler
- Céphalées persistantes secondaires à une injection de dalbavancine : à propos d’un cas
- Lila Hamlaoui-Chareuf, Benjamin Valentin, Sophie Putman, Johana Béné, Sandrine Bergeron, Philippe-Alexandre Faure, Caroline Loiez, Barthélémy Lafon-Desmurs, Nicolas Simon, Eric Senneville
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?